West Pharmaceutical Launches Synchrony S1 Prefillable Syringe, Enhancing Drug Delivery Solutions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Source: PRnewswire
- Global Market Launch: West Pharmaceutical Services unveiled the Synchrony S1 prefillable syringe system at Pharmapack 2026 in Paris, marking a significant milestone in global commercialization that is expected to enhance the company's competitiveness in the biopharmaceutical and vaccine markets.
- Product Diversity: The system offers a broad range of options, including 1 ml long and 2.25 ml staked needle choices, catering to the needs of biologics and vaccines, while ensuring safe and effective drug delivery through high-performance NovaPure® and FluroTec™ barrier film plungers.
- Market Demand Insights: Stacey Vaughan, VP at West, highlighted that the introduction of the new system comes at a crucial time due to shifts in the drug pipeline and the rising demand for combination products, addressing the complexities introduced by the transition from hospital to home care.
- Industry Leadership Showcase: West will demonstrate its industry expertise through learning labs and a product gallery at the event, further solidifying its position as a leader in injectable drug delivery solutions.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like WST with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on WST
Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is 348.70 USD with a low forecast of 285.00 USD and a high forecast of 375.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 235.890
Low
285.00
Averages
348.70
High
375.00
Current: 235.890
Low
285.00
Averages
348.70
High
375.00
About WST
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
West Pharmaceutical Services to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: West Pharmaceutical Services will announce its Q4 and full-year 2025 financial results before the market opens on February 12, 2026, which is expected to impact investor confidence.
- Conference Call Details: Following the earnings release, the company will hold a conference call at 8:00 a.m. Eastern Time to discuss the financial results and business expectations, offering participants the option to register in advance for questions.
- Investor Resources: A slide presentation will be made available on the company's website in the Investors section on the day of the call, ensuring that investors can access key information to make informed decisions.
- Company Background: West Pharmaceutical Services generated $2.89 billion in net sales in fiscal year 2024, and as a leading provider of injectable drug solutions, supports customers in delivering over 41 billion components and devices annually.
Continue Reading
West Pharmaceutical Services to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: West Pharmaceutical Services will announce its Q4 and full-year 2025 financial results before the market opens on February 12, 2026, which is expected to significantly impact investor sentiment.
- Conference Call Details: Following the earnings release, the company will hold a conference call at 8:00 a.m. Eastern Time to discuss the financial results and business expectations, with advance registration required for participants to ask questions.
- Investor Resources: A slide presentation will be made available on the day of the call in the Investors section of the company's website, ensuring that investors have access to critical information to support their decision-making.
- Company Overview: In fiscal year 2024, West generated $2.89 billion in net sales, positioning itself as a leading provider of innovative injectable solutions, delivering over 41 billion components and devices annually, which underscores its strong market presence.
Continue Reading